Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment

Urology

Volumn 51, Issue 4, 1998, Pages 585-589

  Jiborn, Thomas ^a   Bjartell, Anders ^b   Abrahamsson, Per Anders ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CASTRATION; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL TRIAL; HISTOPATHOLOGY; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE SYSTEM; ORCHIECTOMY; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA;

EID: 0031947318     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00684-5     Document Type: Article

References (41)

1. di Sant'Agnese PA: Neuroendocrine differentiation in carcinoma of the prostate. Cancer 70(suppl): 254-268, 1992.
2. Tutton PJM, and Barkla DH: Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells (review). Anticancer Res 7: 1-12, 1987.
3. Seuwen K, and Pouyssegur J: Serotonin as a growth factor. Biochem Pharmacol 39: 985-990, 1990.
4. Zachary I, Woll PJ, and Rozengurt E: A role for neuropeptides in the control of cell proliferation. Dev Biol 124: 295-308, 1987.
5. Dalsgård CJ, Hultgårdh A, Hägerstrand A, and Nilsson J: Neuropeptides as growth factors. Possible roles in human diseases. Regul Pept 25: 1-9, 1989.
6. Bologna M, Festuccia C, Muzi P, Biordi L, and Ciomei M: Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 63: 1714-1720, 1989.
7. Dauge MC, and Delmas V: APUD type endocrine tumor of the prostate: incidence and prognosis in association with adenocarcinoma, in Murphy GP, Khoury S, Kuss R, et al (Eds): Progress in Clinical and Biological Medicine. New York, Liss, 1986, pp 529-531.
8. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, and Ordonez NG: Small cell carcinoma of the prostate: part I. A clinicopathologic study of 20 cases. Cancer 59: 1803-1809, 1987.
9. Almagro UA, Tieu TM, Remeniuk E, Kueck R, and Stumpf K: Argyrophilic, "carcinoid-like" prostatic carcinoma. Arch Pathol Lab Med 110: 916-919, 1986.
10. Abrahamsson PA, Wadström LB, Alumets J, Falkmer S, and Grimelius L: Peptide-hormone- and serotonin-immunoreactive cells in carcinoma of the prostate. Pathol Res Pract 182: 298-307, 1987.
11. Abrahamsson P-A, Falkmer S, Fält K, and Grimelius L: The course of neuroendocrine differentiation in prostatic carcinomas: an immunohistochemical study testing chromogranin A as an "endocrine marker." Pathol Res Pract 185: 373-380, 1989.
12. Cohen RJ, Glezerson G, Haffejee Z, and Afrika D: Prostatic carcinoma: histological and immunohistological factors affecting prognosis. Br J Urol 66: 405-410, 1990.
13. Tarle M, and Rados N: Investigation on serum neuron-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay. Prostate 19: 23-33, 1991.
14. Kadmon D, Thompson T, Lynch G, and Scardino P: Elevated plasma chromogranin A concentrations in prostatic carcinoma. J Urol 146: 358-361, 1991.
15. Aprikian AG, Cordon Cardo C, Fair WR, and Reuter VE: Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 71: 3952-3965, 1993.
16. Paul R, Chang P, di Sant'Agnese PA, Cockett ATK, and Abrahamsson P-A: Prognostic significance of neuroendocrine differentiation in human benign prostate and prostatic carcinoma. J Urol 149(suppl): 480A, 1993.
17. de Matteis A: Tissue markers in the diagnosis and prognosis of prostatic carcinoma. Eur Urol 21(suppl 1): 66-70, 1992.
18. Krijnen JLM, Janssen PJA, Ruizeveld de Winter JA, van Krimpen H, Schröder FH, and van der Kwast TH: Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 100: 393-398, 1993.
19. Bonkhoff H, Stein U, and Remberger K: Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Archiv A Pathol Anat 423: 291-294, 1993.
20. Mostofi FK: Problems of grading carcinoma of prostate. Semin Oncol 3: 161-169, 1976.
21. Deftos LJ, Nakada S, Burton DW, di Sant'Agnese PA, Cockett ATK, and Abrahamsson PA: Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 48: 58-62, 1996.
22. Huttner WB, Gerdes H-H, and Rosa P: The granin (chromogranin/secretogranin) family. Trends Biochem Sci 16: 27-30, 1991.
23. Russell J, Gee P, Liu SM, and Angeletti RH: Inhibition of parathyroid hormone secretion by amino-terminal chromogranin peptides. Endocrinology 135: 337-342, 1994.
24. Schmid KD, Helpap B, Tötsch M, Kirchmair R, Dockhorn-Dworniczak B, Böcker W, and Fischer-Colbrie R: Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate. Histopathology 24: 233-239, 1994.
25. Elias JM, Margiotta M, and Gaborc D: Sensitivity and detection efficiency of the peroxidase antiperoxidase (PAP), avidin-biotin peroxidase complex (ABC), and peroxidase-labeled avidin-biotin (LAB) methods. Am J Clin Pathol 92: 62-67, 1989.
26. Noordzij MA, van Weerden WM, de Ridder CMA, van der Kwast TH, Schröder FH, and van Steenbrugge GJ: Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol 149: 859-871, 1996.
27. Andrew A, Kramer B, and Rawden BB: Gut and pancreatic amine precursor uptake and decarboxylation cells are not neural crest derivatives. Gastroenterology 84: 429-431, 1983.
28. Cussenot O, Berthon P, Cochand-Priollet B, Maitland NJ, and Le Due A: Immunocytochemical comparison of cultured normal epithelial prostatic cells with prostatic tissue sections. Exp Cell Res 214: 83-92, 1994.
29. Merchant DJ, Clarke SM, Ives K, and Harris S: Primary explant culture: an in vitro model of the human prostate. Prostate 4: 523-542, 1983.
30. Aumüller G: Morphological and endocrine aspects of prostatic function. Prostate 4: 195-214, 1983.
31. Bonkhoff H, Stein U, and Remberger K: Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 25: 42-46, 1994.
32. Peehl DM, Leung GK, and Wong ST: Keratin expression: a measure of phenotypic modulation of human prostatic epithelial cells by growth inhibitory factors. Cell Tissue Res 277: 11-18, 1994.
33. Cohen RJ, and Glezerson G: Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer. Arch Pathol Lab Med 116: 65-66, 1992.
34. Jelbart ME, Russell PJ, Russell P, Wass J, Fullerton M, Wills EJ, and Raghavan D: Site-specific growth of the prostate xenograft line UCRY-PR-2. Prostate 14: 163-175, 1989.
35. Mabry M, Nakagawa T, Baylin S, Pettengill O, Sorenson G, and Nelkin B: Insertion of the v-Ha-ras oncogene induces differentiation of calcitonin-producing human small cell lung cancer. J Clin Invest 84: 194-199, 1989.
36. de Bruine AP, Dinjens WNM, van der Linden EPM, Pijls MMJ, Moerkerk PT, and Bosman FT: Extracellular matrix components induce endocrine differentiation in vitro in NCI-H716 cells. Am J Pathol 142: 773-782, 1993.
37. Pfeiffer AMA, Mark GE III, Malan Shelby L, Graziano S, Amstad P, and Harris CC: Cooperation of c-raf-1 and c-myc protooncogenes in the neoplastic transformation of simian virus 40 large tumor antigen-immortalized human bronchial epithelial cells. Proc Natl Acad Sci USA 86: 10075-10079, 1989.
38. Frkovic Grazio S, Kraljic I, Trnski D, and Tarle M: Immunohistochemical staining and serotest markers during development of a sarcomatoid and small cell prostate tumor. Anticancer Res 14: 2151-2156, 1994.
39. Li X, and Drucker DJ: Parathyroid hormone-related peptide is a downstream target for ras and src activation. J Biol Chem 269: 6263-6266, 1994.
40. Rozengurt E, and Sinnett-Smith J: Early signals underlying the induction of the c-fos and c-myc genes in quiescent fibroblasts: studies with bombesin and other growth factors. Prog Nucl Acid Res Mol Biol 35: 261-295, 1988.
41. Rozengurt E: Neuropeptides as cellular growth factors: role of multiple signalling pathways. Eur J Clin Invest 21: 123-134, 1991.